Ischemic cardiomyopathy is the disease condition that occurs when the main heart muscle gets enlarged and dilated due to weakening of heart muscles. This condition leads to either heart attack or coronary disease leading to narrowing of the arteries. These narrowed arteries inhibit the heart’s ability to pump blood and sometimes lead to heart failure. The clinical symptoms of ischemic cardiomyopathy includes shortness of breath, dizziness, extreme fatigue, chest pain and pressure, weight gain, heart palpitations, swelling in legs, insomnia and cough or congestion in lungs. Ischemic cardiomyopathy market can be differentiated through two major prospects namely the diagnostic techniques and treatment methods. On the basis of the diagnostic techniques, the ischemic cardiomyopathy market is segmented as follows:
- Blood tests
- Imaging tests
- Electrocardiogram (ECG)
- Stress test
- Coronary angiography
- Myocardial biopsy
ECG is the most preferred technique used for diagnosis of ischemic cardiomyopathy. It is used to record electrical activity in the heart. Imaging tests including X-ray, computed tomography scan and magnetic resonance imaging form the second line of diagnostics, which is used for studying anatomy of heart. Other tests including blood tests, echocardiogram, stress test and coronary angiography are performed to study other ischemic cardiomyopathy associated factors such as cholesterol, heart activity during exercise and triglycerides level. Myocardial biopsy captures the small share of the ischemic cardiomyopathy market and is performed very rarely, to study tissue sample for determining cause of the disease.
On the basis of the treatment methods, the ischemic cardiomyopathy market has been categorized into two segments namely medications and surgery. Medications are majorly provided to improve cardiac function and to treat symptoms and prevent complications during the disease. On the basis of medications, the ischemic cardiomyopathy market has been segmented as follows:
- ACE inhibitors
- Aldosterone inhibitors
Beta-blockers including carvidelol and metoprolol and ACE inhibitors including captopril, enalapril, lisinopril and ramipril capture the major share of the ischemic cardiomyopathy medications market. These medications are used for reducing blood pressure and for management of heart rate. Aldosterone inhibitors and diuretics are used for removing excess body fluid which results in controlled blood pressure. The major diuretics used for ischemic cardiomyopathy includes thiazide, loop-diuretics and potassium-sparing diuretics. Vasodilators including isosorbide dinitrate and hydralazine are used for dilating blood vessels to prevent the formation of blood clots. On the basis of surgical treatment, the ischemic cardiomyopathy market has been segmented as follows:
- Implanting devices
- Radiation therapy
Implanting devices such as pacemakers and implantable cardiac defibrillators are implanted for normalizing the heart beat. Angioplasty is used to open narrowed arteries and stents are the tubes which are inserted in body to hold arteries open. Atherectomy and radiation therapy are used for removing plague from arteries and to keep arteries clean from angioplasty.
Additionally, many market players are currently developing the drugs for treatment of ischemic cardiomyopathy. As for instance, one of the market players Amgen, Inc. has developed the drug Omecamtiv Mecarbil for the treatment of ischemic cardiomyopathy. Currently, the drug is under phase II clinical trials and on the basis of phase I results, it has been predicted that this drug will be beneficial for the treatment of ischemic cardiomyopathy in future and will help the market to grow. Additionally, the support from government in spreading awareness about the disease in Asia-Pacific region is also fuelling the ischemic cardiomyopathy market growth. As for instance, Cardiomyopathy Association of Australia, Ltd. has been formed by Australian Government to increase public awareness of cardiomyopathy. The increasing awareness in emerging economies is helping the growth of ischemic cardiomyopathy market.
Geographically, the ischemic cardiomyopathy market has been segmented into four main regions including North America, Europe, Asia-Pacific and Rest of the World. Other major market players which are involved in research and development activities of ischemic cardiomyopathy treatment drugs include Bioheart, Inc., Cytokinetics, Inc and LG Life Sciences, Ltd.
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Rest of the World
This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments